Michael F. Hogan, PhD1
doi : 10.1001/jamapsychiatry.2023.0038
June 2023, Vol 80, No. 6, Pages 528-651
Nick Kerman, PhD1; Sean A. Kidd, PhD1,2; Vicky Stergiopoulos, MD1,2
Jacob S. Aday, PhD1; Robin L. Carhart-Harris, PhD1; Joshua D. Woolley, PhD, MD1,2
Ebenezer Oloyede, MPharm1,2; David Taylor, PhD3,4; James MacCabe, PhD1,5
Martin Brüne, MD, PhD1
Benjamin L. Hankin, PhD1; Catherine H. Demers, PhD2,3; Ella-Marie P. Hennessey, MA2; Sarah E. D. Perzow, PhD2; Mary C. Curran, MSW5; Robert J. Gallop, PhD6; M. Camille Hoffman, MD, MSc3,4; Elysia Poggi Davis, PhD2,7
doi : 10.1001/jamapsychiatry.2023.0702
Importance Prenatal depression is prevalent with negative consequences for both the mother and developing fetus. Brief, effective, and safe interventions to reduce depression during pregnancy are needed.
Elodie Blouzard, MSc1; Arnaud Pouchon, MD1,2; Mircea Polosan, PhD1,2; Julien Bastin, PhD1; Clément Dondé, PhD1,2,3
doi : 10.1001/jamapsychiatry.2023.0553
Importance Motivational impairments in schizophrenia are by definition associated with poor outcome. It is postulated that the reduction of goal-directed behavior arises from abnormal trade-offs between rewards and efforts.
Axel Baptista, MD, PhD1,2,3,4; Valérian Chambon, PhD1; Nicolas Hoertel, MD, PhD2,5,6; Mark Olfson, MD, PhD7; Carlos Blanco, MD, PhD8; David Cohen, MD, PhD3,9; Pierre O. Jacquet, PhD4,10,11
doi : 10.1001/jamapsychiatry.2023.0694
Importance Borderline personality disorder (BPD) is often accompanied by a history of high-risk sexual behavior and somatic comorbidities. Yet, these features are most often considered in isolation and little is known about their underlying developmental pathways. Life history theory, a leading framework in evolutionary developmental biology, can help make sense of the wide range of behaviors and health issues found in BPD.
Ye Ella Tian, MBBS, PhD1; Maria A. Di Biase, PhD1; Philip E. Mosley, MD, PhD2,3,4; Michelle K. Lupton, PhD5; Ying Xia, PhD4; Jurgen Fripp, PhD4; Michael Breakspear, MD, PhD6,7; Vanessa Cropley, PhD1; Andrew Zalesky, PhD1,8
doi : 10.1001/jamapsychiatry.2023.0791
Importance Physical health and chronic medical comorbidities are underestimated, inadequately treated, and often overlooked in psychiatry. A multiorgan, systemwide characterization of brain and body health in neuropsychiatric disorders may enable systematic evaluation of brain-body health status in patients and potentially identify new therapeutic targets.
Ian C. Fischer, PhD1,2; Brandon Nichter, PhD2; Peter J. Na, MD, MPH2,3; Sonya B. Norman, PhD4,5,6; John H. Krystal, MD1,2; Robert H. Pietrzak, PhD, MPH1,2,7
doi : 10.1001/jamapsychiatry.2023.0393
Importance Concerns have been raised since the onset of the COVID-19 pandemic that vulnerable populations, such as military veterans, may be at increased risk of suicidal thoughts and behaviors (STBs).
Rebecca Cooper, MPO1; Maria A. Di Biase, PhD2,3,4; Bei Bei, PhD5; Jon Quach, PhD6,7; Vanessa Cropley, PhD1
doi : 10.1001/jamapsychiatry.2023.0379
Importance Sleep problems and psychopathology symptoms are highly comorbid and bidirectionally correlated across childhood and adolescence. Whether these associations are specific to discrete profiles of sleep problems and specific internalizing and externalizing phenomena is currently unclear.
Najaf Amin, PhD1; Jun Liu, PhD1; Bruno Bonnechere, PhD1,2,3; Siamak MahmoudianDehkordi, PhD4; Matthias Arnold, PhD4,5; Richa Batra, PhD6; Yu-Jie Chiou, MSc1,7; Marco Fernandes, PhD8; M. Arfan Ikram, PhD9; Robert Kraaij, PhD10; Jan Krumsiek, PhD6; Danielle Newby, PhD8; Kwangsik Nho, PhD11; Djawad Radjabzadeh, MSc10; Andrew J. Saykin, PhD11; Liu Shi, PhD8; William Sproviero, PhD8; Laura Winchester, PhD8; Yang Yang, PhD1,12; Alejo J. Nevado-Holgado, PhD8; Gabi Kastenmüller, PhD5; Rima Kaddurah-Daouk, PhD4; Cornelia M. van Duijn, PhD1
doi : 10.1001/jamapsychiatry.2023.0685
Importance Metabolomics reflect the net effect of genetic and environmental influences and thus provide a comprehensive approach to evaluating the pathogenesis of complex diseases, such as depression.
Breda Cullen, PhD1; Marc J. Gameroff, PhD2,3; Joey Ward, PhD1; Mark E. S. Bailey, PhD4; Donald M. Lyall, PhD1; Laura M. Lyall, PhD1; Niamh MacSweeney, BA5,6; Eleanor Murphy, PhD2,3; Natasha Sangha, MSc1; Xueyi Shen, PhD5; Rona J. Strawbridge, PhD1,7; Milenna T. van Dijk, PhD2,3; Xingxing Zhu, MSc1; Daniel J. Smith, MD5,6; Ardesheer Talati, PhD2,3; Heather C. Whalley, PhD5,6; Jonathan Cavanagh, MD8; Myrna M. Weissman, PhD2,3,9
doi : 10.1001/jamapsychiatry.2023.0716
Importance Cognitive impairment in depression is poorly understood. Family history of depression is a potentially useful risk marker for cognitive impairment, facilitating early identification and targeted intervention in those at highest risk, even if they do not themselves have depression. Several research cohorts have emerged recently that enable findings to be compared according to varying depths of family history phenotyping, in some cases also with genetic data, across the life span.
Nili Solomonov, PhD1; Jihui Lee, PhD2; Samprit Banerjee, PhD, MStat3; Serena Z. Chen, BA1; Jo Anne Sirey, PhD1; Faith M. Gunning, PhD1; Connor Liston, MD, PhD4; Patrick J. Raue, PhD5; Patricia A. Areán, PhD5; George S. Alexopoulos, MD1
doi : 10.1001/jamapsychiatry.2023.0815
Importance Approximately half of older adults with depression remain symptomatic at treatment end. Identifying discrete clinical profiles associated with treatment outcomes may guide development of personalized psychosocial interventions.
Hui Chen, BS1; Klodian Dhana, PhD2,3; Yuhui Huang, BS1; Liyan Huang, BS1; Yang Tao, MS1; Xiaoran Liu, PhD2,3; Debora Melo van Lent, PhD4,5,6; Yan Zheng, MD, PhD7; Alberto Ascherio, MD, DrPH8; Walter Willett, MD, DrPH8; Changzheng Yuan, ScD1,8
doi : 10.1001/jamapsychiatry.2023.0800
Importance Dementia threatens the well-being of older adults, making efforts toward prevention of great importance.
Kara S. Bagot, MD1,2; Dost Öngür, MD, PhD3,4
Vikas Menon, MD1; Natarajan Varadharajan, MD2; Abdul Faheem, MD1; Chittaranjan Andrade, MD3
doi : 10.1001/jamapsychiatry.2023.0562
Importance The relative efficacy of ketamine and electroconvulsive therapy (ECT) in adults with major depressive episode (MDE) needs clarification.
Marta Cano, PhD1,2; Joan A. Camprodon, MD, PhD2
Mark Olfson, MD, MPH1; Candace M. Cosgrove, MPH2; Melanie M. Wall, PhD1; Carlos Blanco, MD, PhD3
Vani Pariyadath, PhD1
Michael Eriksen Benros, MD, PhD1; Rosa Lundbye Allesøe, MSc1; Simon Rasmussen, PhD2
Troels Boldt Rømer, MD1; Rune Haubo Christensen, PhD1; Michael Eriksen Benros, MD, PhD1
Mette Bliddal, PhD1; Rikke Wesselhoeft, PhD2; Anton Pottegård, PhD2
John C. Fortney, PhD1
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟